Trial Profile
A retrospective study to compare the efficacy of intravitreal Ranibizumab and intravitreal Aflibercept in patients with neovascular wet age related macular degeneration(AMD) affected eyes with or without choroidal vascular hyperpermeability (CVH).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 13 Dec 2015 New trial record